Guardant Health (GH) — AI Analysis & Mentions

Guardant Health is up 47% in a month and 207% in a year, reflecting excitement around its non-invasive cancer diagnostics. But with DCF valuations ranging widely ($128.33 vs $209.53 fair value), investors should keep an eye on cash burn and regulatory risk. Growth stories can produce large short-term swings but are best approached with a long-term horizon and keen attention to fundamentals.